These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27459537)

  • 21. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.
    Muskiet MH; Tonneijck L; Smits MM; Kramer MH; Diamant M; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2016 Feb; 18(2):178-85. PubMed ID: 26636423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice.
    Fosgerau K; Jessen L; Lind Tolborg J; Østerlund T; Schæffer Larsen K; Rolsted K; Brorson M; Jelsing J; Skovlund Ryge Neerup T
    Diabetes Obes Metab; 2013 Jan; 15(1):62-71. PubMed ID: 22862961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from the saliva of the Gila monster.
    Alves PL; Abdalla FMF; Alponti RF; Silveira PF
    Toxicon; 2017 Sep; 135():1-11. PubMed ID: 28579479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models.
    Gorgogietas V; Rajaei B; Heeyoung C; Santacreu BJ; Marín-Cañas S; Salpea P; Sawatani T; Musuaya A; Arroyo MN; Moreno-Castro C; Benabdallah K; Demarez C; Toivonen S; Cosentino C; Pachera N; Lytrivi M; Cai Y; Carnel L; Brown C; Urano F; Marchetti P; Gilon P; Eizirik DL; Cnop M; Igoillo-Esteve M
    Diabetologia; 2023 Jul; 66(7):1306-1321. PubMed ID: 36995380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity: a strategy for production of pancreatic beta-cell lines for use in transplantation.
    Chepurny OG; Holz GG
    Cell Tissue Res; 2002 Feb; 307(2):191-201. PubMed ID: 11845326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway.
    Jia Y; Gong N; Li TF; Zhu B; Wang YX
    Pharmacol Res; 2015 Dec; 102():276-85. PubMed ID: 26546042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
    Consoli A; Di Biagio R
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
    Oeseburg H; de Boer RA; Buikema H; van der Harst P; van Gilst WH; Silljé HH
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1407-14. PubMed ID: 20448207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Influences of exendin-4 on the secretion function of islet beta cells from rats in the early stage of severe scald].
    Zhao DX; Ma L; Shen ZA; Li DW; Shang YR; Yin K; Cheng WF; Wang X; Liu ZX
    Zhonghua Shao Shang Za Zhi; 2016 Dec; 32(12):752-758. PubMed ID: 28043300
    [No Abstract]   [Full Text] [Related]  

  • 32. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
    Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
    Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucagon-like peptide-1 stimulates type 3 iodothyronine deiodinase expression in a mouse insulinoma cell line.
    Akiyama S; Ogiwara T; Aoki T; Tsunekawa K; Araki O; Murakami M
    Life Sci; 2014 Oct; 115(1-2):22-8. PubMed ID: 25241124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
    Fernández-García JC; Colomo N; Tinahones FJ
    Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of glucagon-like peptide-1 on the beta cell.
    Vilsbøll T
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats.
    Rudinsky AJ; Adin CA; Borin-Crivellenti S; Rajala-Schultz P; Hall MJ; Gilor C
    Domest Anim Endocrinol; 2015 Apr; 51():78-85. PubMed ID: 25594949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon-like peptide 1 protects INS-1E mitochondria against palmitate-mediated beta-cell dysfunction: a proteomic study.
    Ciregia F; Giusti L; Ronci M; Bugliani M; Piga I; Pieroni L; Rossi C; Marchetti P; Urbani A; Lucacchini A
    Mol Biosyst; 2015 Jun; 11(6):1696-707. PubMed ID: 25912719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
    J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues.
    Tews D; Werner U; Eckel J
    Horm Metab Res; 2008 Mar; 40(3):172-80. PubMed ID: 18348079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.